$7.70
2.26% yesterday
Nasdaq, Dec 24, 09:39 pm CET
ISIN
US09058V1035
Symbol
BCRX

BioCryst Pharmaceuticals, Inc. Stock price

$7.70
+0.87 12.74% 1M
-2.23 22.46% 6M
+0.18 2.39% YTD
+0.03 0.39% 1Y
-3.75 32.75% 3Y
+0.42 5.77% 5Y
-3.02 28.17% 10Y
-9.93 56.32% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.17 2.26%
ISIN
US09058V1035
Symbol
BCRX
Industry

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
$2.1b
Net debt
$461.5m
Cash
$212.9m
Shares outstanding
210.5m
Valuation (TTM | estimate)
P/E
negative | 45.5
P/S
2.7 | 2.6
EV/Sales
3.5 | 3.3
EV/FCF
63.1
P/B
negative
Financial Health
Equity Ratio
-97.1%
Return on Equity
18.7%
ROCE
29.7%
ROIC
50.1%
Debt/Equity
-1.7
Financials (TTM | estimate)
Revenue
$599.8m | $630.9m
EBITDA
$77.4m | $102.7m
EBIT
$76.1m | $112.6m
Net Income
$-8.8m | $35.6m
Free Cash Flow
$33.0m
Growth (TTM | estimate)
Revenue
45.4% | 40.0%
EBITDA
296.7% | 7,998.5%
EBIT
286.9% | 4,533.5%
Net Income
92.9% | 140.0%
Free Cash Flow
158.2%
Margin (TTM | estimate)
Gross
97.4%
EBITDA
12.9% | 16.3%
EBIT
12.7%
Net
-1.5% | 5.6%
Free Cash Flow
5.5%
More
EPS
$-0.1
FCF per Share
$0.2
Short interest
17.8%
Employees
580
Rev per Employee
$780.0k
Show more

Is BioCryst Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

BioCryst Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:

14x Buy
88%
2x Hold
13%

Analyst Opinions

16 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast:

Buy
88%
Hold
13%

Financial data from BioCryst Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
600 600
45% 45%
100%
- Direct Costs 16 16
96% 96%
3%
584 584
44% 44%
97%
- Selling and Administrative Expenses 333 333
33% 33%
56%
- Research and Development Expense 175 175
11% 11%
29%
77 77
297% 297%
13%
- Depreciation and Amortization 1.30 1.30
4% 4%
0%
EBIT (Operating Income) EBIT 76 76
287% 287%
13%
Net Profit -8.78 -8.78
93% 93%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about BioCryst Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioCryst Pharmaceuticals, Inc. Stock News

Positive
Reuters
13 days ago
The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to under 12 years, the company said on Friday.
Neutral
GlobeNewsWire
13 days ago
– ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions in monthly attack rates in APeX-P– RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Fo...
Neutral
GlobeNewsWire
21 days ago
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted four newly-hired employees stock options to purchase an aggregate of 57,100 shares, and restricted stock units (RSUs) covering an aggregate of 46,400 shares, of BioCryst common stock.
More BioCryst Pharmaceuticals, Inc. News

Company Profile

BioCryst Pharmaceuticals, Inc. designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.

Head office United States
CEO Jon Stonehouse
Employees 580
Founded 1986
Website www.biocryst.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today